Researchers at SfN 2015 outlined perinatal treatments that rescued cognition in mouse models of the disease.
The RNA-binding protein hnRNP A3 can help rid a cell of the repeat RNAs, but the RNAs interfere with its nuclear localization.
Research presented at SfN strengthens the case that microglia gorge on synapses in some neurodegenerative and neurodevelopmental disorders.
The ALS-linked RNA may convert free-floating proteins to liquid phase droplets.
Phenotypes vary depending on the partial or full-length nature of the C9ORF72 transgene.
Basic science inspires conference goers in Chicago.
White-matter hyperintensities, astrocyte damage, hypoperfusion, and amyloid angiopathy draw scrutiny as factors in the complex relationship between cerebrovascular and neurodegenerative processes in dementia.
Scientists struggle to understand neurodegeneration in the SNAP syndrome.
Scanning for amyloid plaques in the brain may help clinicians diagnose and manage patients with a questionable diagnosis of Alzheimer’s.
The largest trial yet of ApoE4 carriers is pioneering new protocols with increasing use of technology to reach thousands of potential participants and disclose risk information.
Prevention trials are testing new protocols for telling potential participants about their heightened risk for dementia, and exploring the psychological effect of such disclosures.
The synaptic protein abounds in the cerebrospinal fluid of AD patients and in those in the prodromal phase of the disease.
Research uncovers subtle links between early development problems and some forms of dementia.
Variability still plagues CSF biomarker measurements, but automated systems offer hope of a diagnostic assay.
Scientists are coming to grips with how tau spreads, and what the consequences are for the brain.